Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Rusconi C, Cheah CY, Eyre TA, Tucker D, Klener P, Giné E, Crucitti L, Muzi C, Iadecola S, Infante G, Bernard S, Auer RL, Pagani C, Duglosz-Danecka M, Mocikova H, van Meerten T, Cencini E, Marin-Niebla A, Williams ME, Angelillo P, Nicoli P, Arcari A, Morello L, Mannina D, Vitagliano O, Sartori R, Chiappella A, Sciarra R, Stefani PM, Dreyling M, Seymour JF, Visco C. Rusconi C, et al. Among authors: marin niebla a. Blood. 2022 Oct 27;140(17):1907-1916. doi: 10.1182/blood.2022015560. Blood. 2022. PMID: 35789260 Free article.
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.
Visco C, Di Rocco A, Evangelista A, Quaglia FM, Tisi MC, Morello L, Zilioli VR, Rusconi C, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Marin-Niebla A, McCulloch R, Gini G, Perrone T, Nassi L, Pennese E, Stefani PM, Cox MC, Bozzoli V, Fabbri A, Polli V, Ferrero S, Celis MIA, Sica A, Petrucci L, Arcaini L, Rule S, Krampera M, Vitolo U, Balzarotti M. Visco C, et al. Leukemia. 2021 Mar;35(3):787-795. doi: 10.1038/s41375-020-01013-3. Epub 2020 Aug 11. Leukemia. 2021. PMID: 32782382
Correction: Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.
Visco C, Di Rocco A, Evangelista A, Quaglia FM, Tisi MC, Morello L, Zilioli VR, Rusconi C, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Marin-Niebla A, McCulloch R, Gini G, Perrone T, Nassi L, Pennese E, Stefani PM, Cox MC, Bozzoli V, Fabbri A, Polli V, Ferrero S, De Celis MIA, Sica A, Petrucci L, Arcaini L, Rule S, Krampera M, Vitolo U, Balzarotti M. Visco C, et al. Leukemia. 2021 Mar;35(3):932. doi: 10.1038/s41375-020-01119-8. Leukemia. 2021. PMID: 33483620 No abstract available.
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma.
Iacoboni G, Rejeski K, Villacampa G, van Doesum JA, Chiappella A, Bonifazi F, Lopez-Corral L, van Aalderen M, Kwon M, Martínez-Cibrian N, Bramanti S, Reguera-Ortega JL, Camacho-Arteaga L, Schmidt C, Marín-Niebla A, Kersten MJ, Martin Garcia-Sancho A, Zinzani PL, Corradini P, van Meerten T, Subklewe M, Barba P. Iacoboni G, et al. Among authors: marin niebla a. Blood Adv. 2022 Jun 28;6(12):3606-3610. doi: 10.1182/bloodadvances.2021006922. Blood Adv. 2022. PMID: 35271707 Free PMC article. No abstract available.
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
Giné E, de la Cruz F, Jiménez Ubieto A, López Jimenez J, Martín García-Sancho A, Terol MJ, González Barca E, Casanova M, de la Fuente A, Marín-Niebla A, Muntañola A, González-López TJ, Aymerich M, Setoain X, Cortés-Romera M, Rotger A, Rodríguez S, Medina Herrera A, García Sanz R, Nadeu F, Beà S, Campo E, López-Guillermo A. Giné E, et al. Among authors: marin niebla a. J Clin Oncol. 2022 Apr 10;40(11):1196-1205. doi: 10.1200/JCO.21.02321. Epub 2022 Jan 14. J Clin Oncol. 2022. PMID: 35030036 Free PMC article. Clinical Trial.
A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression.
Abrisqueta P, Medina D, Villacampa G, Lu J, Alcoceba M, Carabia J, Boix J, Tazón-Vega B, Iacoboni G, Bobillo S, Marín-Niebla A, González M, Zenz T, Crespo M, Bosch F. Abrisqueta P, et al. Among authors: marin niebla a. Blood Adv. 2022 Nov 8;6(21):5763-5773. doi: 10.1182/bloodadvances.2022007508. Blood Adv. 2022. PMID: 35973197 Free PMC article.
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies.
Jiménez M, Roldán E, Fernández-Naval C, Villacampa G, Martinez-Gallo M, Medina-Gil D, Peralta-Garzón S, Pujadas G, Hernández C, Pagès C, Gironella M, Fox L, Orti G, Barba P, Pumarola T, Cabirta A, Catalá E, Valentín M, Marín-Niebla A, Orfao A, González M, Campins M, Ruiz-Camps I, Valcárcel D, Bosch F, Hernández M, Crespo M, Esperalba J, Abrisqueta P. Jiménez M, et al. Blood Adv. 2022 Feb 8;6(3):774-784. doi: 10.1182/bloodadvances.2021006101. Blood Adv. 2022. PMID: 34844263 Free PMC article.
Variant t(11;22)(q13;q11.2) with IGL involvement in mantle cell lymphoma.
Cabirta A, Hidalgo-Gómez G, Marín-Niebla A, Gallur L, Saumell S, Castellví J, Catalá E, Blanco A, López-Andreoni L, Montoro MJ, Navarrete M, Palacio-García C, Tazón-Vega B, Bobillo S, Bosch F, Ortega M. Cabirta A, et al. Among authors: marin niebla a. Leuk Lymphoma. 2022 Jul;63(7):1746-1749. doi: 10.1080/10428194.2022.2034158. Epub 2022 Feb 7. Leuk Lymphoma. 2022. PMID: 35129412 No abstract available.
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
Sancho JM, Marín-Niebla A, Fernández S, Capote FJ, Cañigral C, Grande C, Donato E, Zeberio I, Puerta JM, Rivas A, Pérez-Ceballos E, Vale A, Martín García-Sancho A, Salar A, González-Barca E, Teruel A, Pastoriza C, Conde-Royo D, Sánchez-García J, Barrenetxea C, Arranz R, Hernández-Rivas JÁ, Ramírez MJ, Jiménez A, Rubio-Azpeitia E. Sancho JM, et al. Among authors: marin niebla a. Int J Hematol. 2022 Sep;116(3):381-392. doi: 10.1007/s12185-022-03367-z. Epub 2022 May 13. Int J Hematol. 2022. PMID: 35551632 Free PMC article.
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.
Panayiotidis P, Tumyan G, Thieblemont C, Ptushkin VV, Marin-Niebla A, García-Sanz R, Le Gouill S, Stathis A, Bottos A, Hamidi H, Katz P, Perretti T, Willis JC, Buske C. Panayiotidis P, et al. Among authors: marin niebla a. Leuk Lymphoma. 2022 May;63(5):1058-1069. doi: 10.1080/10428194.2021.2015765. Epub 2022 Jan 19. Leuk Lymphoma. 2022. PMID: 35045765 Clinical Trial.
32 results